Status: Recruiting
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Participants needed: 18
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Nov 4, 2025Locations: 10
Eligibility criteria
Participants must be ≥ 18 years of age or age considered as adult in the respect... [+16]
Women who are pregnant, planning to become pregnant during the study, or are bre... [+16]